TABLE 2.

Dose-escalation schedule for canine patients

Dose level	Dose of MO32* plaque forming units (pfu)
	Stage 1	Stage 2
Level 1	1 × 106 pfu
Level 2	1 × 107 pfu
Level 3	1 × 108 pfu	1 × 108 pfu + 1,200 mg/M2 Indoximod
Level 4	1 × 109 pfu

Modified with permission from Chambers MR, Bentley RT, Crossman DK, Foote JB, Koehler JW, Markert JM, Omar NB, Platt SR, Self DM, Shores A, Sorjonen DC, Waters AM, Yanke AB and Gillespie GY (2020). The One Health Consortium: design of a phase I clinical trial to evaluate M032, a genetically engineered HSV-1 expressing IL-12, in combination with a checkpoint inhibitor in canine patients with sporadic high grade gliomas. Front. Surg. 7:59. Copyright 2020, the Authors. CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/).

^*Doses are stated as exact doses in plaque forming units rather than as a percentage.